AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

AbbVie Inc.NYSE: ABBV

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue declines year over year

Q3 FY2026 cost of revenue of $2.62B fell 50.7% year over year, behind the -13.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 39.0% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Cost of revenue amounted to 29.8% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -50.7% toward the trailing-twelve-month pace of -13.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.62B-39.0% QoQ
Last fiscal yearDec 2025
$18.2B+7.7% YoY
LTMSep 2026
$15.68B-13.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.7%——
1 year+7.7%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
18.2B USD
Year-over-year change
+7.7%
4-year CAGR
+1.1%

Cost of Revenue vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.1% is the 9th highest of 10, against a peer median of +4.5%.
  • Cost of revenue amounts to 23.7% of revenue for ABBV, versus a peer median of 26.8%.
ABBV Competitors
Cost of Revenue for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$30.98B USD+5.3%+7.1%31.2%
PFEPfizer Inc.LTM Jun 2026$17.08B USD-4.0%-22.4%26.8%
MRKMerck & Co., Inc.LTM Jun 2026$16.35B USD+4.5%+1.5%24.6%
ABBVAbbVie Inc.LTM Sep 2026$15.68B USD-13.1%+1.5%23.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$14.68B USD+3.6%+11.2%29.8%
NVSNovartis AGLTM Jun 2026$14.22B USD+8.5%+5.7%25.6%
LLYEli Lilly and CompanyLTM Jun 2026$13.23B USD+43.0%+18.6%16.6%
AZNAstraZeneca PLCLTM Sep 2026$12.38B USD+20.9%-5.0%19.9%
AMGNAmgen Inc.LTM Jun 2026$10.43B USD-15.9%+18.8%27.3%
GSKGSK plcLTM Jun 2026£9.06B GBP-0.0%-1.9%27.3%
Peer median (excluding ABBV) —+4.5%+5.7%26.8%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.